Innate Pharma (IPHA) Competitors

Innate Pharma (NASDAQ:IPHA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Do institutionals & insiders hold more shares of IPHA or RCKT?

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to IPHA or RCKT?

In the previous week, Rocket Pharmaceuticals had 17 more articles in the media than Innate Pharma. MarketBeat recorded 20 mentions for Rocket Pharmaceuticals and 3 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.87 beat Rocket Pharmaceuticals' score of 0.95 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rocket Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer IPHA or RCKT?

Innate Pharma currently has a consensus target price of $11.50, suggesting a potential upside of 502.09%. Rocket Pharmaceuticals has a consensus target price of $43.00, suggesting a potential upside of 558.50%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Rocket Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the MarketBeat Community believe in IPHA or RCKT?

Rocket Pharmaceuticals received 350 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 73.38% of users gave Rocket Pharmaceuticals an outperform vote while only 59.49% of users gave Innate Pharma an outperform vote.

Company	Underperform	Outperform
Innate Pharma	Outperform Votes 47 59.49%	Underperform Votes 32 40.51%
Rocket Pharmaceuticals	Outperform Votes 397 73.38%	Underperform Votes 144 26.62%

Which has higher valuation and earnings, IPHA or RCKT?

Innate Pharma has higher revenue and earnings than Rocket Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$12.63M	12.67	-$8.19M	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$245.60M	-$2.73	-2.39

Which has more volatility and risk, IPHA or RCKT?

Innate Pharma has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Is IPHA or RCKT more profitable?

Innate Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-62.62%	-54.17%

Summary

Innate Pharma beats Rocket Pharmaceuticals on 8 of the 15 factors compared between the two stocks.